Acrotech Biopharma — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Total funding raised: $25M

Overview

Acrotech Biopharma is a private, commercial-stage biopharmaceutical company established to develop and bring to market innovative therapies. Its strategy is growth-oriented, leveraging collaborations to build expertise and commercial infrastructure to maximize product value. The company emphasizes a patient-focused, research-based approach, aiming to make treatments accessible while working closely with all healthcare stakeholders from development through commercialization.

BiologicsSmall Molecules

Technology Platform

Strategy focused on developing therapies across two modalities: Biologics and Small Molecules. Growth and expertise are planned through collaborations.

Funding History

1

Total raised:$25M

Series A$25MMar 15, 2021

Opportunities

The strategy to target both biologics and small molecules allows access to a broad range of high-value therapeutic areas with unmet needs.

Building a commercial platform focused on the U.S.

market first provides a clear path to capturing value in the world's largest pharmaceutical market if products are successfully developed and approved.

Risk Factors

Extreme lack of public information on pipeline, leadership, and financing creates high uncertainty and makes risk assessment difficult.

The company's asset-light, collaboration-dependent model carries execution risk, as progress is contingent on securing high-quality partnerships and in-licensing deals in a competitive environment.

Competitive Landscape

Acrotech operates in the highly competitive global biopharmaceutical industry, competing for scientific talent, partnership opportunities, investment capital, and ultimately, market share. Its success depends on identifying and developing differentiated assets that can compete against those of large pharmaceutical companies and other more established biotechs.

More companies in Small Molecule Drugs →More companies in United States →